Amylin CEO on Exenatide

[cnbc 3000056194]

Dan Bradbury, Amylin CEO, discusses paying Lilly $250M upfront and $1.2B of future sales for the rights to Exenatide, the once weekly version of diabetes drug, Byetta, that’s pending FDA approval.

Melissa Lee anchors a fast-paced discussion among four professional Wall Street traders. An hour after the bell Fast Money hosts one of the best trading discussions of the day.

Video © and provided by CNBC.

Be the first to comment

Leave a Reply